Innate Pharma (IPHA) Revenue (2020 - 2024)

Innate Pharma (IPHA) has 5 years of Revenue data on file, last reported at $13.5 million in Q4 2024.

• For the quarter ending Q4 2024, Revenue fell 75.85% year-over-year to $13.5 million; the trailing twelve-month figure through Dec 2024 stood at $116.7 million (down 35.65% YoY), and the FY2025 full-year result was $3.2 million, down 84.91% from the prior year.
• Revenue for Q4 2024 stood at $13.5 million, up from $8.9 million in the prior quarter.
• Across five years, Revenue topped out at $67.0 million in Q4 2020 and bottomed at $8.9 million in Q2 2024.
• The 5-year median for Revenue is $33.4 million (2021), against an average of $35.6 million.
• The widest annual swing landed in 2023, when Revenue jumped 169.17%; it then slumped 76.8% in 2024.
• A 5-year view of Revenue shows it stood at $67.0 million in 2020, then tumbled by 57.79% to $28.3 million in 2021, then surged by 108.22% to $58.8 million in 2022, then slipped by 5.1% to $55.8 million in 2023, then tumbled by 75.85% to $13.5 million in 2024.
• The last three Revenue figures came in at $13.5 million (Q4 2024), $8.9 million (Q2 2024), and $55.8 million (Q4 2023), per Business Quant data.

Peer Comparison